You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 醫藥股普漲 中生製藥(1177.HK)漲逾3%
格隆匯 12-17 10:29
格隆匯12月17日丨港股醫藥股普漲,其中,東陽光藥(1558.HK)漲逾4%,中生製藥(1177.HK)漲逾3%,四環醫藥、石藥集團等漲逾2%。個股方面,中生製藥昨晚發公告稱,附屬公司的抗腫瘤藥“注射用硼替佐米”已獲國家藥監局頒發藥品補充申請批件;東陽光藥近日斥2700萬元人民幣設合營推進宜都基地醫藥中間體項目。板塊方面,昨日(12月16日),恆生指數公司宣佈推出包括香港上巿生物科技指數等在內的四項新指數。恆生香港上巿生物科技指數反映香港上市生物科技公司之整體表現,投資者對生物科技公司的興趣日漸增加,這項指數為市場提供一個指標以量度該行業類別之表現。分析人士表示,醫藥領域的投資機會集中在創新驅動和政策鼓勵兩個方向。長期看,政策將持續有利於醫藥行業發展,隨着核心競爭力逐漸脱穎而出,龍頭公司有望獲得更多市場份額。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account